Agounitestane D, Chiheb M, Khaled S, Ait Khaled N, Boulahbal F, Chaulet P
Clinique Matiben, Hôpital de Béni-Messous, Centre Hospitalier Universitaire d'Alger-Ouest, Algérie.
Rev Mal Respir. 1990;7(3):209-13.
250 patients suffering from pulmonary tuberculosis who were smear positive received a chemotherapy regime for 6 months combining Rifampicin and Isoniazid every day with a daily supplement of Pyrazinamide for the first 8 weeks. The three drugs given in the initial phase of treatment were administered either separately or in combined preparations according to the 2 controlled randomised groups. During the maintenance phase the drugs were given in a combined form in fixed proportions in the 2 groups. 6 months after the end of treatment the bacteriological results were similar in the 2 groups in the 144 cases which were analysed. Amongst 137 cases with bacilli which were initially sensitive to Isoniazid (68 cases with separate medicines at the beginning and 69 with combined drugs) there was no failure at 6 months, nor any relapse during the course of the first period of surveillance. Amongst 7 cases with bacilli which were originally resistant to Isoniazid (4 and 3 respectively), there were 2 failures at 6 months one in each group with acquired resistance to Rifampicin observed at the time of the failure. There was no difference in the therapeutic results observed whatever the presentation of drugs used during the initial phase of treatment.
250例痰涂片阳性的肺结核患者接受了为期6个月的化疗方案，每天联合使用利福平与异烟肼，并在最初8周每日补充吡嗪酰胺。根据2个对照随机分组，治疗初始阶段给予的3种药物分别单独给药或制成复方制剂给药。在维持阶段，两组均以固定比例制成复方形式给药。治疗结束6个月后，在分析的144例病例中，两组的细菌学结果相似。在137例最初对异烟肼敏感的杆菌病例中（开始时68例单独用药，69例联合用药），6个月时无治疗失败病例，在首个监测期内也无复发。在7例最初对异烟肼耐药的杆菌病例中（分别为4例和3例），6个月时有2例治疗失败，每组各1例，失败时观察到对利福平获得性耐药。无论治疗初始阶段使用何种剂型的药物，观察到的治疗结果均无差异。
